Topic:

M&A

Latest Headlines

Latest Headlines

Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M

Clinical stage allergy player Circassia Pharmaceuticals, which had a huge $332 million IPO on the London Stock Exchange last year, will scoop up Swedish asthma company Aerocrine for SEK 1.78 billion ($214.3 million) after it got its latest asthma diagnostic device cleared by FDA in November.

Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line

NantWorks, the nebulous empire of biotech billionaire Patrick Soon-Shiong, is handing over $90 million to partner Sorrento Therapeutics in exchange for a Phase III cancer drug heralded as a successor to the blockbuster Abraxane.

Circassia snags a pair of asthma biotechs for $371M

Circassia, the U.K. biotech that pulled off a major IPO last year, spent a combined $371 million on two asthma-focused drug developers in an effort to expand its pipeline beyond its home turf of allergy immunotherapies.

Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds

Last year, Mylan forked over millions to cover its top execs' tax liability on its deal with Abbott Laboratories, which shifted its tax domicile to Europe. Investors weren't so lucky--and now, they may take another tax hit if Mylan joins up with suitor Teva.

Physician services player Mednax buys into teleradiology with $500M vRad acquisition

Mednax has built its $6.7 billion business by providing specialized, outsourced services to hospitals for everything from neonatal, anesthesia, maternal-fetal to pediatric physician subspecialties. Now it's added teleradiology to that mix with the purchase of Virtual Radiologic (vRad) for $500 million in cash.

MorphoSys swoops for Lanthio as biotech investment plan matures

MorphoSys has acquired Lanthio Pharma. The deal comes 30 months after MorphoSys originally hooked up with Lanthio, which was the first company to receive an investment from its biotech financing initiative.

Danaher, drawn by Pall's biopharma biz, will pay $13.8B for filtration specialist

Drugmakers are developing more biologic drugs and building new plants to manufacture them. And given that those plants all need filtration systems, analysts say it is no wonder that Pall would become a buyout prize. The Port Washington, NY-based company is being scooped up in $13.8 billion deal that rivals those orchestrated by some of its pharma clients.

Danaher buys water-systems maker for $13.8B, will split into two companies

With its largest acquisition ever, of filtration and purification system maker Pall for $13.8 billion, Danaher decided it had the ammunition to break itself into two publicly traded companies. The company's life science and technology units will retain the name Danaher, while a smaller company consisting of Danaher's diverse industrial businesses will be formed in late-2016.

WuXi weighs going private with a deal on the table

WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.

Baxter pads biopharma unit with pre-spinoff oncology buy

As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it's bulking up.